Novo Nordisk’ chief executive Lars Fruergaard ... be the only industry representative in the GLP-1 agonist market to testify at the hearing. President Donald Trump said he will sign an order ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

In response to the news on Tuesday, the stock prices of Novo Nordisk and Hims & Hers shot up, with the latter stock price rising by nearly $10. Ro CEO Zach Reitano said, “Adding Novo Nordisk’s ...

The main story of the earnings report was Novo Nordisk's 2025 guidance, which calls for sales to grow from 13% to 21%. CEO Lars Fruergaard Jorgensen said that the company is "actively focused on ...

Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the reduced forecast to rising competition from compounded weight loss drugs in the U.S. "In the first quarter of 2025, we delivered 18% ...

"We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications," Hims & Hers CEO Andrew Dudum said in a statement.

Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's ...

Drugmaker Novo Nordisk NVO-N expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after ...

"Growth is expected to pick up in the second-half of the year," CEO Lars Fruergaard Jorgensen said on a call with journalists. Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion ...